Rigel Pharmaceuticals (RIGL) Q3 Earnings and Revenues Top EstimatesZacks Investment Research • 11/07/24
Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and ExpositionPRNewsWire • 11/05/24
Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business UpdatePRNewsWire • 10/31/24
Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)PRNewsWire • 10/24/24
Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®GlobeNewsWire • 10/16/24
Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic PartnershipsSeeking Alpha • 10/10/24
Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains?Zacks Investment Research • 09/25/24
Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AMLPRNewsWire • 09/05/24
Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and TaiwanPRNewsWire • 09/03/24
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/06/24
Rigel Reports Second Quarter 2024 Financial Results and Provides Business UpdatePRNewsWire • 08/06/24
Rigel Pharmaceuticals (RIGL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 07/30/24
Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business UpdatePRNewsWire • 07/30/24
Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow PotentialSeeking Alpha • 07/24/24
Optime Care Announces Enhanced Partnership with Rigel Pharmaceuticals for GAVRETO® PatientsBusiness Wire • 06/27/24
Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug ApplicationPRNewsWire • 06/24/24